VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $131,000 | -15.5% | 9,041 | +42.7% | 0.00% | -20.0% |
| Q3 2016 | $155,000 | -46.4% | 6,335 | -55.9% | 0.01% | -50.0% |
| Q2 2016 | $289,000 | +60.6% | 14,349 | +109.7% | 0.01% | +25.0% |
| Q1 2016 | $180,000 | -29.4% | 6,842 | +172.7% | 0.01% | -33.3% |
| Q4 2015 | $255,000 | -81.1% | 2,509 | -66.8% | 0.01% | -88.6% |
| Q3 2015 | $1,347,000 | -11.3% | 7,554 | +10.6% | 0.10% | -2.8% |
| Q2 2015 | $1,518,000 | +37.7% | 6,831 | +23.1% | 0.11% | +40.3% |
| Q1 2015 | $1,102,000 | +125.4% | 5,548 | +62.3% | 0.08% | +45.3% |
| Q4 2014 | $489,000 | +12.7% | 3,418 | +3.4% | 0.05% | +1.9% |
| Q3 2014 | $434,000 | -47.1% | 3,305 | -49.1% | 0.05% | -52.7% |
| Q2 2014 | $820,000 | -53.4% | 6,499 | -51.2% | 0.11% | -14.1% |
| Q1 2014 | $1,758,000 | +71.8% | 13,328 | +53.0% | 0.13% | -17.9% |
| Q4 2013 | $1,023,000 | +33.0% | 8,713 | +18.2% | 0.16% | +16.4% |
| Q3 2013 | $769,000 | +2.9% | 7,372 | -15.0% | 0.13% | -10.7% |
| Q2 2013 | $747,000 | – | 8,678 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |